News | Analytics Software | October 06, 2015

Deal will create structured, mineable repository of de-identified thoracic tumor descriptors to evaluate samples for imaging biomarkers

HealthMyne Inc, Moffitt Cancer Center, imaging analytics technology agreement, thoracic oncology

Image courtesy of Siemens Healthcare


October 6, 2015 — HealthMyne Inc., a clinical imaging informatics company, has agreed to a research and product evaluation agreement with Moffitt Cancer Center. The primary objective of the agreement is the implementation of an imaging analytics software platform, with an initial focus on thoracic oncology.

One important component of the technology agreement is a structured, mineable repository of de-identified tumor descriptors that will allow investigators to evaluate samples for imaging biomarkers.  “The tumor characterization and data mining capabilities that the HealthMyne solution provides will help to accelerate our efforts to identify and validate important radiomic signatures,” said Robert J. Gillies, Ph.D., chair of the Department of Cancer Imaging and Metabolism at Moffitt.  “We have moved from viewing images as pictures to seeing them as data, and that is a very empowering clinical care step.”

For more information: www.healthmyne.com


Additional Content

News | FDA

April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...

Time April 20, 2026
arrow
News | Digital Pathology

Feb. 11, 2026 — Leica Biosystems has announced the global launch of the Leica CM1950 Cryostat with DualEcoTec Cooling ...

Time February 11, 2026
arrow
News | RSNA

Jan. 22, 2026 — The nomination deadline for the 2026 RSNA Rising Star Award is approaching. The Rising Star Award is ...

Time January 22, 2026
arrow
Feature | Cybersecurity | Kyle Hardner

As radiology practices shift toward cloud-based platforms and integrate AI-powered tools, will practices become more ...

Time January 14, 2026
arrow
News | Radiation Oncology

Jan. 8, 2026 — RefleXion Medical, an external-beam theranostic oncology company, has announced the U.S. Food and Drug ...

Time January 13, 2026
arrow
Subscribe Now